Pharmacologic inhibition of AQP4—alone or in combination with ion channel modulators—has shown promise in preclinical models by reducing glioma cell motility, sensitizing tumors to standard therapies, and suppressing recurrence (Varricchio et al., 2021; Varricchio and Yool, 2023). The gene discussed is AQP4; the disease is central nervous system cancer.